Single agent anti‐PD1 therapy, anti‐CTLA4 therapy or combination immunotherapy is associated with long term survival in a real‐world population of both treatment naïve and pre‐treated patients with advanced melanoma, NSCLC and RCC. Here, CTLA4 is linked to renal cell carcinoma.